Anterior EEG slowing in dementia with Lewy bodies: a multicenter European cohort study.


Journal

Neurobiology of aging
ISSN: 1558-1497
Titre abrégé: Neurobiol Aging
Pays: United States
ID NLM: 8100437

Informations de publication

Date de publication:
09 2020
Historique:
received: 04 09 2019
revised: 19 04 2020
accepted: 21 04 2020
pubmed: 26 5 2020
medline: 16 1 2021
entrez: 26 5 2020
Statut: ppublish

Résumé

Electroencephalography (EEG) slowing with prealpha dominant frequency (DF) in posterior derivations is a biomarker for dementia with Lewy bodies (DLB) diagnosis, in contrast with Alzheimer's disease (AD). However, an intrasubject re-evaluation of the original data, which contributed to the identification of EEG DLB biomarker, showed that DF was slower in anterior than posterior derivations. We suppose this anterior-posterior gradient of DF slowing could arise in DLB from a thalamocortical dysrhythmia, differently involving the anterior and posterior cortical areas, and correlating with cognitive impairment (Mini-Mental State Examination). EEG was recorded in 144 DLB, 116 AD, and 65 controls from 7 Centers of the European DLB Consortium. Spectra were divided into delta, theta, prealpha, alpha frequency bands. In DLB, mean DF was prealpha both anteriorly and posteriorly, but lower anteriorly (p < 0.001). In 14% of DLB, DF was prealpha anteriorly, whereas alpha posteriorly. In AD and controls, DF was constantly alpha. EEG slowing in DLB correlated with cognitive impairment. Thalamocortical dysrhythmia gives rise to prealpha rhythm with an anterior-posterior gradient and correlates with impaired cognition.

Identifiants

pubmed: 32450445
pii: S0197-4580(20)30143-3
doi: 10.1016/j.neurobiolaging.2020.04.023
pii:
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

55-60

Subventions

Organisme : Department of Health
Pays : United Kingdom

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Raffaella Franciotti (R)

Department of Neuroscience, Imaging and Clinical Science, and Aging Research Centre, G. d'Annunzio University of Chieti-Pescara, Chieti, Italy.

Andrea Pilotto (A)

Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.

Davide V Moretti (DV)

Alzheimer's Epidemiology and Rehabilitation in Alzheimer's Disease Operative Unit, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.

Nicola Walter Falasca (NW)

Department of Neuroscience, Imaging and Clinical Science, and Aging Research Centre, G. d'Annunzio University of Chieti-Pescara, Chieti, Italy.

Dario Arnaldi (D)

Clinical Neurology, Department of Neuroscience (DINOGMI), University of Genoa and IRCCS AOU San Martino-IST, Genoa, Italy; IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

John-Paul Taylor (JP)

Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne, UK.

Flavio Nobili (F)

Clinical Neurology, Department of Neuroscience (DINOGMI), University of Genoa and IRCCS AOU San Martino-IST, Genoa, Italy; IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

Milica Kramberger (M)

Department of Neurology, University Medical Centre, Ljubljana, Slovenia.

Sara Garcia Ptacek (SG)

Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Karolinska Institutet, and Memory Clinic Department of Geriatric Medicine, Karolinska University Hospital, Stockholm, Sweden.

Alessandro Padovani (A)

Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.

Dag Aarlsand (D)

King's College of London, London, UK.

Marco Onofrj (M)

Department of Neuroscience, Imaging and Clinical Science, and Aging Research Centre, G. d'Annunzio University of Chieti-Pescara, Chieti, Italy.

Laura Bonanni (L)

Department of Neuroscience, Imaging and Clinical Science, and Aging Research Centre, G. d'Annunzio University of Chieti-Pescara, Chieti, Italy. Electronic address: l.bonanni@unich.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH